ENB-0040 is a bone targeted enzyme replacement therapy designed to directly target TNSALP to the bone in order to correct the enzyme deficiency, which could result in restoration of normal bone mineralisation.
The Phase II study will evaluate ENB-0040 in adolescents and adults with hypophosphatasia (HPP).
Upon completion of the study, which is anticipated later this year, Enobia Pharma will have collected safety and efficacy data for ENB-0040 in HPP patients of all ages.
If approved, ENB-0040 would be the first available treatment for patients with HPP.
ENB-0040 was granted orphan designation in the US and EU in 2008 and Fast Track status in 2009.